A new study shows that inhaled insulin is successful in treating Type 1 diabetes.
Despite advances in insulin treatment options, glucose control for people with diabetes still proves difficult.
MannKind Corp. recently funded a study that was a four-week trial in multiple locations.
MannKind Corp. ushers the discovery, development and commercialization of therapeutic products for patients with diabetes, pulmonary arterial hypertension and other diseases.
Study participants were men and women between 18 and 70 with Type 1 diabetes who injected insulin at least three times per day with stable insulin doses for a month prior to the study.
Participants needed to have a certain body mass index, be regular eaters and meet a list of other criteria.
The goal was to examine how a new product called Technosphere Insulin worked compared to insulin currently on the market.
Technosphere Insulin is a new powdered formula that is inhaled instead of traditional insulin, which is injected.
Technosphere Insulin was compared to Insulin Aspart, considered fast-acting and well known, that is injected.
Technosphere Insulin was successful when used at mealtimes as patients were able to inhale the Technosphere Insulin as a supplement.
Glucose levels appeared to be more stable with the use of Technosphere Insulin, more so than Insulin Aspart but both proved effective.
Technosphere Insulin also reduced hypoglycemia duration.
The research grant for the inhaled insulin study from MannKind Corp. was through the University of Colorado.
Using this study as a foundation, a larger study group would be beneficial to confirm and expand on these findings.
